Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the middle east respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Lan, Jiaming ^a,b   Deng, Yao ^a   Chen, Hong ^a   Lu, Guangwen ^c   Wang, Wen ^a   Guo, Xiaojuan ^a   Lu, Zhuozhuang ^a   Gao, George F ^c   Tan, Wenjie ^a  

^a BEIJING HOSPITAL   (China)

^b HEBEI MEDICAL UNIVERSITY   (China)

^c INSTITUTE OF MICROBIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; FREUND ADJUVANT; IMMUNOGLOBULIN G ANTIBODY; IMMUNOLOGICAL ADJUVANT; NEUTRALIZING ANTIBODY; POLYINOSINIC ACID; RECEPTOR BINDING DOMAIN PROTEIN; SUBUNIT VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CORONAVIRUS; DRUG ADMINISTRATION ROUTE; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; T LYMPHOCYTE; VACCINATION; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DRUG DELIVERY SYSTEM; IMMUNIZATION; IMMUNOLOGY; PROCEDURES;

CORONAVIRUS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, VIRAL; DRUG DELIVERY SYSTEMS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNIZATION; MICE; MICE, INBRED BALB C; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; VIRAL VACCINES;

EID: 84913534501     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0112602     Document Type: Article

References (36)

1. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA (2012) Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 367: 1814-1820.
2. Lu L, Liu Q, Du L, Jiang S (2013) Middle East respiratory syndrome coronavirus (MERS-CoV): challenges in identifying its source and controlling its spread. Microbes Infect 15: 625-629.
3. WHO (2014) Middle East respiratory syndrome coronavirus (MERS-CoV) - update.
4. Azhar EI, El-Kafrawy SA, Farraj SA, Hassan AM, Al-Saeed MS, et al. (2014) Evidence for camel-to-human transmission of MERS coronavirus. N Engl J Med 370: 2499-2505.
5. Samara EM, Abdoun KA (2014) Concerns about Misinterpretation of Recent Scientific Data Implicating Dromedary Camels in Epidemiology of Middle East Respiratory Syndrome (MERS). MBio 5.
6. Reusken C, Farag E, Jonges M, Godeke G, El-Sayed A, et al. (2014) Middle East respiratory syndrome coronavirus (MERS-CoV) RNA and neutralising antibodies in milk collected according to local customs from dromedary camels, Qatar, April 2014. Euro Surveill 19.
7. Ma C, Li Y, Wang L, Zhao G, Tao X, et al. (2014) Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines. Vaccine 32: 2100-2108.
8. Du L, Kou Z, Ma C, Tao X, Wang L, et al. (2013) A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines. PLoS One 8: e81587.
9. Du L, Zhao G, Kou Z, Ma C, Sun S, et al. (2013) Identification of a receptorbinding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development. J Virol 87: 9939-9942.
10. Mou H, Raj VS, van Kuppeveld FJM, Rottier PJM, Haagmans BL, et al. (2013) The Receptor Binding Domain of the New Middle East Respiratory Syndrome Coronavirus Maps to a 231-Residue Region in the Spike Protein That Efficiently Elicits Neutralizing Antibodies. Journal of Virology 87: 9379-9383.
11. De Gregorio E, Caproni E, Ulmer JB (2013) Vaccine adjuvants: mode of action. Front Immunol 4: 214.
12. Haining WN, Anderson DG, Little SR, von Bergwelt-Baildon MS, Cardoso AA, et al. (2004) pH-triggered microparticles for peptide vaccination. J Immunol, 173: 2578-2585.
13. Oleszycka E, Lavelle EC (2014) Immunomodulatory properties of the vaccine adjuvant alum. Current Opinion in Immunology 28: 1-5.
14. Steinhagen F, Kinjo T, Bode C, Klinman DM (2011) TLR-based immune adjuvants. Vaccine 29: 3341-3355.
15. Conforti VA, de Avila DM, Cummings NS, Zanella R, Wells KJ, et al. (2008) CpG motif-based adjuvant as a replacement for Freund's complete adjuvant in a recombinant LHRH vaccine. Vaccine 26: 907-913.
16. Stahl-Hennig C, Eisenblatter M, Jasny E, Rzehak T, Tenner-Racz K, et al. (2009) Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques. PLoS Pathog 5: e1000373.
17. Chuai X, Chen H, Wang W, Deng Y, Wen B, et al. (2013) Poly(I:C)/alum mixed adjuvant priming enhances HBV subunit vaccine-induced immunity in mice when combined with recombinant adenoviral-based HBV vaccine boosting. PLoS One 8: e54126.
18. Wang J, Tricoche N, Du L, Hunter M, Zhan B, et al. (2012) The adjuvanticity of an O. volvulus-derived rOv-ASP-1 protein in mice using sequential vaccinations and in non-human primates. PLoS One. 7: e37019.
19. Cribbs DH, Ghochikyan A, Vasilevko V, Tran M, Petrushina I, et al. (2003) Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol, 15: 505-514.
20. Leroux-Roels G (2010) Unmet needs in modern vaccinology: Adjuvants to improve the immune response. Vaccine 28 Suppl 3: C25-C36.
21. Lu G, Hu Y, Wang Q, Qi J, Gao F, et al. (2013) Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 500: 227-231.
22. Vermont CL, van Dijken HH, van Limpt CJ, de Groot R, van Alphen L, et al. (2002) Antibody avidity and immunoglobulin G isotype distribution following immunization with a monovalent meningococcal B outer membrane vesicle vaccine. Infect Immun 70: 584-590.
23. Zhao G, Du L, Ma C, Li Y, Li L, et al. (2013) A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV. Virol J 10: 266.
24. Zhao J, Li K, Wohlford-Lenane C, Agnihothram SS, Fett C, et al. (2014) Rapid generation of a mouse model for Middle East respiratory syndrome. Proc Natl Acad Sci USA 111: 4970-4975.
25. Zhu X, Liu Q, Du L, Lu L, Jiang S (2013) Receptor-binding domain as a target for developing SARS vaccines. J Thorac Dis 5: S142-S148.
26. Jiang S, Bottazzi ME, Du L, Lustigman S, Tseng CT, et al. (2012) Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome. Expert Rev Vaccines 11: 1405- 1413.
27. Chan JF, Li KS, To KK, Cheng VC, Chen H, et al. (2012) Is the discovery of the novel human betacoronavirus 2c EMC/2012 (HCoV-EMC) the beginning of another SARS-like pandemic? J Infect 65: 477-489.
28. Lau SK, Li KS, Tsang AK, Lam CS, Ahmed S, et al. (2013) Genetic characterization of Betacoronavirus lineage C viruses in bats reveals marked sequence divergence in the spike protein of pipistrellus bat coronavirus HKU5 in Japanese pipistrelle: implications for the origin of the novel Middle East respiratory syndrome coronavirus. J Virol 87: 8638-8650.
29. Raj VS, Mou H, Smits SL, Dekkers DH, Muller MA, et al. (2013) Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 495: 251-254.
30. Kester KE, Cummings JF, Ofori-Anyinam O, Ockenhouse CF, Krzych U, et al. (2009) Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS, S/AS01B and RTS, S/AS02A in malaria-naive adults: Safety, efficacy, and immunologic associates of protection. J Infect Dis 200: 337-346.
31. Dychter SS, Gold DA, Haller MF (2012) Subcutaneous drug delivery: A route to increased safety, patient satisfaction, and reduced costs. J Infus Nurs 35: 154- 160.
32. Gong M, Zhou J, Yang C, Deng Y, Zhao G, et al. (2012) Insect cell-expressed hemagglutinin with CpG oligodeoxynucleotides plus alum as an adjuvant is a potential pandemic influenza vaccine candidate. Vaccine 30: 7498-7505.
33. Schijns VE, Lavelle EC (2011) Trends in vaccine adjuvants. Expert Review of Vaccines 10: 539-550.
34. Sanchez Vallecillo MF, Ullio Gamboa GV, Palma SD, Harman MF, Chiodetti AL, et al. (2014) Adjuvant activity of CpG-ODN formulated as a liquid crystal. Biomaterials 35: 2529-2542.
35. Munster VJ, de Wit E, Feldmann H (2013) Pneumonia from human coronavirus in a macaque model. N Engl J Med 368: 1560-1562.
36. de Wit E, Prescott J, Baseler L, Bushmaker T, Thomas T, et al. (2013) The Middle East respiratory syndrome coronavirus (MERS-CoV) does not replicate in Syrian hamsters. PLoS One 8: e69127.